nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—Cholecalciferol—Calcitriol—psoriasis	0.26	1	CiPCiCtD
Paricalcitol—Calcipotriol—psoriasis	0.0885	0.416	CrCtD
Paricalcitol—VDR—psoriasis	0.0882	1	CbGaD
Paricalcitol—Calcitriol—psoriasis	0.067	0.316	CrCtD
Paricalcitol—chronic kidney failure—Calcitriol—psoriasis	0.0659	0.54	CpDpCtD
Paricalcitol—Cholecalciferol—psoriasis	0.057	0.268	CrCtD
Paricalcitol—chronic kidney failure—Cholecalciferol—psoriasis	0.056	0.46	CpDpCtD
Paricalcitol—CYP24A1—Calcipotriol—psoriasis	0.0425	0.296	CbGbCtD
Paricalcitol—VDR—Calcipotriol—psoriasis	0.0337	0.235	CbGbCtD
Paricalcitol—CYP24A1—Calcitriol—psoriasis	0.0287	0.2	CbGbCtD
Paricalcitol—VDR—Calcitriol—psoriasis	0.0228	0.159	CbGbCtD
Paricalcitol—VDR—Cholecalciferol—psoriasis	0.0117	0.0817	CbGbCtD
Paricalcitol—Dihydrotachysterol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Cholecalciferol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Calcitriol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Alfacalcidol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Calcidiol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Ergocalciferol—Calcipotriol—psoriasis	0.00992	0.0694	CrCrCtD
Paricalcitol—Dihydrotachysterol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Cholecalciferol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Calcidiol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Alfacalcidol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Ergocalciferol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Calcipotriol—Calcitriol—psoriasis	0.00752	0.0526	CrCrCtD
Paricalcitol—Alfacalcidol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—Calcitriol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—Calcidiol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—Dihydrotachysterol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—Calcipotriol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—Ergocalciferol—Cholecalciferol—psoriasis	0.00639	0.0447	CrCrCtD
Paricalcitol—CYP3A4—Calcitriol—psoriasis	0.000813	0.00566	CbGbCtD
Paricalcitol—CYP3A4—Methoxsalen—psoriasis	0.000632	0.0044	CbGbCtD
Paricalcitol—VDR—vertebral column—psoriasis	0.000451	0.513	CbGeAlD
Paricalcitol—CYP3A4—Cholecalciferol—psoriasis	0.000419	0.00292	CbGbCtD
Paricalcitol—CYP3A4—Mycophenolate mofetil—psoriasis	0.000363	0.00253	CbGbCtD
Paricalcitol—CYP3A4—Triamcinolone—psoriasis	0.000363	0.00253	CbGbCtD
Paricalcitol—CYP3A4—Betamethasone—psoriasis	0.000312	0.00217	CbGbCtD
Paricalcitol—CYP3A4—Prednisolone—psoriasis	0.000308	0.00214	CbGbCtD
Paricalcitol—CYP3A4—Hydrocortisone—psoriasis	0.000292	0.00203	CbGbCtD
Paricalcitol—CYP3A4—Prednisone—psoriasis	0.00029	0.00202	CbGbCtD
Paricalcitol—VDR—skin epidermis—psoriasis	0.000276	0.315	CbGeAlD
Paricalcitol—CYP3A4—Cyclosporine—psoriasis	0.000275	0.00192	CbGbCtD
Paricalcitol—Dihydrotachysterol—VDR—psoriasis	0.000222	0.232	CrCbGaD
Paricalcitol—CYP24A1—Vitamin D Metabolism—VDR—psoriasis	0.000213	0.104	CbGpPWpGaD
Paricalcitol—CYP3A4—Dexamethasone—psoriasis	0.000181	0.00126	CbGbCtD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000174	0.0847	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000172	0.0836	CbGpPWpGaD
Paricalcitol—Calcidiol—VDR—psoriasis	0.000143	0.149	CrCbGaD
Paricalcitol—Alfacalcidol—VDR—psoriasis	0.000143	0.149	CrCbGaD
Paricalcitol—Calcipotriol—VDR—psoriasis	0.000143	0.149	CrCbGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000141	0.0687	CbGpPWpGaD
Paricalcitol—Calcitriol—VDR—psoriasis	0.000128	0.133	CrCbGaD
Paricalcitol—Ergocalciferol—VDR—psoriasis	0.000102	0.106	CrCbGaD
Paricalcitol—VDR—skin of body—psoriasis	8.56e-05	0.0976	CbGeAlD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8e-05	0.0389	CbGpPWpGaD
Paricalcitol—Cholecalciferol—VDR—psoriasis	7.73e-05	0.0806	CrCbGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP2S1—psoriasis	7.5e-05	0.0365	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP2S1—psoriasis	7.4e-05	0.036	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	6.68e-05	0.0325	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	6.59e-05	0.0321	CbGpPWpGaD
Paricalcitol—VDR—tendon—psoriasis	6.52e-05	0.0743	CbGeAlD
Paricalcitol—UGT1A4—Biological oxidations—CYP2S1—psoriasis	6e-05	0.0292	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP2S1—psoriasis	5.91e-05	0.0288	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	5.79e-05	0.0282	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.58e-05	0.0271	CbGpPWpGaD
Paricalcitol—CYP3A4—Xenobiotics—CYP2S1—psoriasis	5.44e-05	0.0265	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.67e-05	0.0227	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—PPARG—psoriasis	4.28e-05	0.0208	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TGFA—psoriasis	3.62e-05	0.0176	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CARM1—psoriasis	3.62e-05	0.0176	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PPARG—psoriasis	3.38e-05	0.0164	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—TGFA—psoriasis	3.34e-05	0.0162	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	3.26e-05	0.0158	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	3.08e-05	0.015	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.87e-05	0.014	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.48e-05	0.0121	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	2.26e-05	0.011	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	2.23e-05	0.0109	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—TARS—psoriasis	2.14e-05	0.0104	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PCNA—psoriasis	1.92e-05	0.00933	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.86e-05	0.00905	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	1.83e-05	0.00891	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	1.81e-05	0.00879	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	1.66e-05	0.00805	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NDUFA5—psoriasis	1.51e-05	0.00734	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.41e-05	0.00684	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CARM1—psoriasis	1.4e-05	0.00682	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP2S1—psoriasis	1.28e-05	0.00624	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NDUFA5—psoriasis	1.21e-05	0.00587	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—JUN—psoriasis	1.07e-05	0.0052	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.04e-05	0.00505	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP2S1—psoriasis	1.03e-05	0.00499	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.73e-06	0.00474	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.6e-06	0.00467	CbGpPWpGaD
Paricalcitol—Hyperhidrosis—Triamcinolone—psoriasis	8.43e-06	0.00031	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.4e-06	0.00409	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.38e-06	0.000308	CcSEcCtD
Paricalcitol—Insomnia—Hydrocortisone—psoriasis	8.38e-06	0.000308	CcSEcCtD
Paricalcitol—Hypertension—Betamethasone—psoriasis	8.37e-06	0.000308	CcSEcCtD
Paricalcitol—Hypertension—Dexamethasone—psoriasis	8.37e-06	0.000308	CcSEcCtD
Paricalcitol—Paraesthesia—Hydrocortisone—psoriasis	8.32e-06	0.000306	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.32e-06	0.000306	CcSEcCtD
Paricalcitol—Urticaria—Cyclosporine—psoriasis	8.28e-06	0.000305	CcSEcCtD
Paricalcitol—Myalgia—Dexamethasone—psoriasis	8.26e-06	0.000304	CcSEcCtD
Paricalcitol—Myalgia—Betamethasone—psoriasis	8.26e-06	0.000304	CcSEcCtD
Paricalcitol—Abdominal pain—Cyclosporine—psoriasis	8.24e-06	0.000303	CcSEcCtD
Paricalcitol—Body temperature increased—Cyclosporine—psoriasis	8.24e-06	0.000303	CcSEcCtD
Paricalcitol—Anxiety—Betamethasone—psoriasis	8.23e-06	0.000303	CcSEcCtD
Paricalcitol—Anxiety—Dexamethasone—psoriasis	8.23e-06	0.000303	CcSEcCtD
Paricalcitol—Vomiting—Mycophenolic acid—psoriasis	8.19e-06	0.000301	CcSEcCtD
Paricalcitol—Discomfort—Dexamethasone—psoriasis	8.16e-06	0.0003	CcSEcCtD
Paricalcitol—Discomfort—Betamethasone—psoriasis	8.16e-06	0.0003	CcSEcCtD
Paricalcitol—Dyspepsia—Hydrocortisone—psoriasis	8.16e-06	0.0003	CcSEcCtD
Paricalcitol—Rash—Mycophenolic acid—psoriasis	8.13e-06	0.000299	CcSEcCtD
Paricalcitol—Dermatitis—Mycophenolic acid—psoriasis	8.12e-06	0.000298	CcSEcCtD
Paricalcitol—Pain—Prednisolone—psoriasis	8.11e-06	0.000298	CcSEcCtD
Paricalcitol—Urticaria—Mycophenolate mofetil—psoriasis	8.08e-06	0.000297	CcSEcCtD
Paricalcitol—Headache—Mycophenolic acid—psoriasis	8.07e-06	0.000297	CcSEcCtD
Paricalcitol—Decreased appetite—Hydrocortisone—psoriasis	8.05e-06	0.000296	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—psoriasis	8.05e-06	0.000296	CcSEcCtD
Paricalcitol—Abdominal pain—Mycophenolate mofetil—psoriasis	8.04e-06	0.000296	CcSEcCtD
Paricalcitol—Body temperature increased—Mycophenolate mofetil—psoriasis	8.04e-06	0.000296	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—psoriasis	8.01e-06	0.000294	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Hydrocortisone—psoriasis	8e-06	0.000294	CcSEcCtD
Paricalcitol—Fatigue—Hydrocortisone—psoriasis	7.99e-06	0.000294	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—psoriasis	7.95e-06	0.000292	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.95e-06	0.000292	CcSEcCtD
Paricalcitol—Pain—Hydrocortisone—psoriasis	7.92e-06	0.000291	CcSEcCtD
Paricalcitol—Oedema—Betamethasone—psoriasis	7.92e-06	0.000291	CcSEcCtD
Paricalcitol—Oedema—Dexamethasone—psoriasis	7.92e-06	0.000291	CcSEcCtD
Paricalcitol—Insomnia—Triamcinolone—psoriasis	7.89e-06	0.00029	CcSEcCtD
Paricalcitol—Infection—Dexamethasone—psoriasis	7.86e-06	0.000289	CcSEcCtD
Paricalcitol—Infection—Betamethasone—psoriasis	7.86e-06	0.000289	CcSEcCtD
Paricalcitol—Ill-defined disorder—Prednisone—psoriasis	7.84e-06	0.000288	CcSEcCtD
Paricalcitol—Paraesthesia—Triamcinolone—psoriasis	7.83e-06	0.000288	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisolone—psoriasis	7.82e-06	0.000287	CcSEcCtD
Paricalcitol—Anaemia—Prednisone—psoriasis	7.81e-06	0.000287	CcSEcCtD
Paricalcitol—Shock—Dexamethasone—psoriasis	7.79e-06	0.000286	CcSEcCtD
Paricalcitol—Shock—Betamethasone—psoriasis	7.79e-06	0.000286	CcSEcCtD
Paricalcitol—Dyspnoea—Triamcinolone—psoriasis	7.78e-06	0.000286	CcSEcCtD
Paricalcitol—Nervous system disorder—Betamethasone—psoriasis	7.76e-06	0.000285	CcSEcCtD
Paricalcitol—Nervous system disorder—Dexamethasone—psoriasis	7.76e-06	0.000285	CcSEcCtD
Paricalcitol—Agitation—Prednisone—psoriasis	7.76e-06	0.000285	CcSEcCtD
Paricalcitol—Angioedema—Prednisone—psoriasis	7.72e-06	0.000284	CcSEcCtD
Paricalcitol—Hypersensitivity—Cyclosporine—psoriasis	7.68e-06	0.000282	CcSEcCtD
Paricalcitol—Dyspepsia—Triamcinolone—psoriasis	7.68e-06	0.000282	CcSEcCtD
Paricalcitol—Nausea—Mycophenolic acid—psoriasis	7.65e-06	0.000281	CcSEcCtD
Paricalcitol—Hyperhidrosis—Dexamethasone—psoriasis	7.65e-06	0.000281	CcSEcCtD
Paricalcitol—Hyperhidrosis—Betamethasone—psoriasis	7.65e-06	0.000281	CcSEcCtD
Paricalcitol—Feeling abnormal—Hydrocortisone—psoriasis	7.63e-06	0.000281	CcSEcCtD
Paricalcitol—Malaise—Prednisone—psoriasis	7.62e-06	0.00028	CcSEcCtD
Paricalcitol—Vertigo—Prednisone—psoriasis	7.59e-06	0.000279	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—psoriasis	7.58e-06	0.000279	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Hydrocortisone—psoriasis	7.58e-06	0.000279	CcSEcCtD
Paricalcitol—Syncope—Prednisone—psoriasis	7.57e-06	0.000279	CcSEcCtD
Paricalcitol—Anorexia—Dexamethasone—psoriasis	7.55e-06	0.000277	CcSEcCtD
Paricalcitol—Anorexia—Betamethasone—psoriasis	7.55e-06	0.000277	CcSEcCtD
Paricalcitol—Urticaria—Prednisolone—psoriasis	7.54e-06	0.000277	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—psoriasis	7.53e-06	0.000277	CcSEcCtD
Paricalcitol—Fatigue—Triamcinolone—psoriasis	7.52e-06	0.000277	CcSEcCtD
Paricalcitol—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.49e-06	0.000276	CcSEcCtD
Paricalcitol—Asthenia—Cyclosporine—psoriasis	7.48e-06	0.000275	CcSEcCtD
Paricalcitol—Pain—Triamcinolone—psoriasis	7.46e-06	0.000274	CcSEcCtD
Paricalcitol—Loss of consciousness—Prednisone—psoriasis	7.42e-06	0.000273	CcSEcCtD
Paricalcitol—Hypotension—Dexamethasone—psoriasis	7.4e-06	0.000272	CcSEcCtD
Paricalcitol—Hypotension—Betamethasone—psoriasis	7.4e-06	0.000272	CcSEcCtD
Paricalcitol—Pruritus—Cyclosporine—psoriasis	7.38e-06	0.000271	CcSEcCtD
Paricalcitol—Urticaria—Hydrocortisone—psoriasis	7.36e-06	0.000271	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—psoriasis	7.36e-06	0.000271	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—psoriasis	7.32e-06	0.000269	CcSEcCtD
Paricalcitol—Body temperature increased—Hydrocortisone—psoriasis	7.32e-06	0.000269	CcSEcCtD
Paricalcitol—Abdominal pain—Hydrocortisone—psoriasis	7.32e-06	0.000269	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—psoriasis	7.31e-06	0.000269	CcSEcCtD
Paricalcitol—Asthenia—Mycophenolate mofetil—psoriasis	7.3e-06	0.000268	CcSEcCtD
Paricalcitol—Hypertension—Prednisone—psoriasis	7.29e-06	0.000268	CcSEcCtD
Paricalcitol—Chills—Methotrexate—psoriasis	7.28e-06	0.000268	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.24e-06	0.00352	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.21e-06	0.000265	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Betamethasone—psoriasis	7.21e-06	0.000265	CcSEcCtD
Paricalcitol—Pruritus—Mycophenolate mofetil—psoriasis	7.2e-06	0.000265	CcSEcCtD
Paricalcitol—Myalgia—Prednisone—psoriasis	7.19e-06	0.000264	CcSEcCtD
Paricalcitol—Arthralgia—Prednisone—psoriasis	7.19e-06	0.000264	CcSEcCtD
Paricalcitol—Feeling abnormal—Triamcinolone—psoriasis	7.19e-06	0.000264	CcSEcCtD
Paricalcitol—Anxiety—Prednisone—psoriasis	7.17e-06	0.000264	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—psoriasis	7.17e-06	0.000263	CcSEcCtD
Paricalcitol—Insomnia—Dexamethasone—psoriasis	7.16e-06	0.000263	CcSEcCtD
Paricalcitol—Insomnia—Betamethasone—psoriasis	7.16e-06	0.000263	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.14e-06	0.000263	CcSEcCtD
Paricalcitol—Diarrhoea—Cyclosporine—psoriasis	7.13e-06	0.000262	CcSEcCtD
Paricalcitol—Paraesthesia—Betamethasone—psoriasis	7.11e-06	0.000261	CcSEcCtD
Paricalcitol—Paraesthesia—Dexamethasone—psoriasis	7.11e-06	0.000261	CcSEcCtD
Paricalcitol—Discomfort—Prednisone—psoriasis	7.1e-06	0.000261	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—psoriasis	7.1e-06	0.000261	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—psoriasis	7.06e-06	0.00026	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—TP53—psoriasis	7.05e-06	0.00343	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Prednisolone—psoriasis	6.99e-06	0.000257	CcSEcCtD
Paricalcitol—Dyspepsia—Betamethasone—psoriasis	6.97e-06	0.000256	CcSEcCtD
Paricalcitol—Dyspepsia—Dexamethasone—psoriasis	6.97e-06	0.000256	CcSEcCtD
Paricalcitol—Diarrhoea—Mycophenolate mofetil—psoriasis	6.96e-06	0.000256	CcSEcCtD
Paricalcitol—Urticaria—Triamcinolone—psoriasis	6.93e-06	0.000255	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—psoriasis	6.91e-06	0.000254	CcSEcCtD
Paricalcitol—Body temperature increased—Triamcinolone—psoriasis	6.9e-06	0.000254	CcSEcCtD
Paricalcitol—Dizziness—Cyclosporine—psoriasis	6.89e-06	0.000253	CcSEcCtD
Paricalcitol—Oedema—Prednisone—psoriasis	6.89e-06	0.000253	CcSEcCtD
Paricalcitol—Decreased appetite—Betamethasone—psoriasis	6.88e-06	0.000253	CcSEcCtD
Paricalcitol—Decreased appetite—Dexamethasone—psoriasis	6.88e-06	0.000253	CcSEcCtD
Paricalcitol—Infection—Prednisone—psoriasis	6.85e-06	0.000252	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Dexamethasone—psoriasis	6.83e-06	0.000251	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Betamethasone—psoriasis	6.83e-06	0.000251	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—psoriasis	6.83e-06	0.000251	CcSEcCtD
Paricalcitol—Hypersensitivity—Hydrocortisone—psoriasis	6.83e-06	0.000251	CcSEcCtD
Paricalcitol—Fatigue—Betamethasone—psoriasis	6.82e-06	0.000251	CcSEcCtD
Paricalcitol—Fatigue—Dexamethasone—psoriasis	6.82e-06	0.000251	CcSEcCtD
Paricalcitol—Shock—Prednisone—psoriasis	6.78e-06	0.000249	CcSEcCtD
Paricalcitol—Pain—Betamethasone—psoriasis	6.77e-06	0.000249	CcSEcCtD
Paricalcitol—Pain—Dexamethasone—psoriasis	6.77e-06	0.000249	CcSEcCtD
Paricalcitol—Nervous system disorder—Prednisone—psoriasis	6.76e-06	0.000249	CcSEcCtD
Paricalcitol—VDR—Gene Expression—CARM1—psoriasis	6.75e-06	0.00328	CbGpPWpGaD
Paricalcitol—Dizziness—Mycophenolate mofetil—psoriasis	6.73e-06	0.000247	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.72e-06	0.00327	CbGpPWpGaD
Paricalcitol—Skin disorder—Prednisone—psoriasis	6.7e-06	0.000246	CcSEcCtD
Paricalcitol—Hyperhidrosis—Prednisone—psoriasis	6.66e-06	0.000245	CcSEcCtD
Paricalcitol—Asthenia—Hydrocortisone—psoriasis	6.65e-06	0.000244	CcSEcCtD
Paricalcitol—Vomiting—Cyclosporine—psoriasis	6.63e-06	0.000244	CcSEcCtD
Paricalcitol—Rash—Cyclosporine—psoriasis	6.57e-06	0.000242	CcSEcCtD
Paricalcitol—Anorexia—Prednisone—psoriasis	6.57e-06	0.000242	CcSEcCtD
Paricalcitol—Dermatitis—Cyclosporine—psoriasis	6.57e-06	0.000241	CcSEcCtD
Paricalcitol—Pruritus—Hydrocortisone—psoriasis	6.55e-06	0.000241	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—psoriasis	6.55e-06	0.000241	CcSEcCtD
Paricalcitol—Headache—Cyclosporine—psoriasis	6.53e-06	0.00024	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—psoriasis	6.52e-06	0.00024	CcSEcCtD
Paricalcitol—Feeling abnormal—Dexamethasone—psoriasis	6.52e-06	0.00024	CcSEcCtD
Paricalcitol—Feeling abnormal—Betamethasone—psoriasis	6.52e-06	0.00024	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Dexamethasone—psoriasis	6.47e-06	0.000238	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Betamethasone—psoriasis	6.47e-06	0.000238	CcSEcCtD
Paricalcitol—Vomiting—Mycophenolate mofetil—psoriasis	6.47e-06	0.000238	CcSEcCtD
Paricalcitol—Hypersensitivity—Triamcinolone—psoriasis	6.43e-06	0.000236	CcSEcCtD
Paricalcitol—Rash—Mycophenolate mofetil—psoriasis	6.41e-06	0.000236	CcSEcCtD
Paricalcitol—Dermatitis—Mycophenolate mofetil—psoriasis	6.41e-06	0.000236	CcSEcCtD
Paricalcitol—Headache—Mycophenolate mofetil—psoriasis	6.37e-06	0.000234	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—psoriasis	6.37e-06	0.000234	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—psoriasis	6.34e-06	0.000233	CcSEcCtD
Paricalcitol—Diarrhoea—Hydrocortisone—psoriasis	6.34e-06	0.000233	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—psoriasis	6.32e-06	0.000232	CcSEcCtD
Paricalcitol—Urticaria—Dexamethasone—psoriasis	6.29e-06	0.000231	CcSEcCtD
Paricalcitol—Urticaria—Betamethasone—psoriasis	6.29e-06	0.000231	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Prednisone—psoriasis	6.28e-06	0.000231	CcSEcCtD
Paricalcitol—Dizziness—Prednisolone—psoriasis	6.27e-06	0.000231	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CARM1—psoriasis	6.26e-06	0.00305	CbGpPWpGaD
Paricalcitol—Asthenia—Triamcinolone—psoriasis	6.26e-06	0.00023	CcSEcCtD
Paricalcitol—Abdominal pain—Dexamethasone—psoriasis	6.26e-06	0.00023	CcSEcCtD
Paricalcitol—Body temperature increased—Dexamethasone—psoriasis	6.26e-06	0.00023	CcSEcCtD
Paricalcitol—Abdominal pain—Betamethasone—psoriasis	6.26e-06	0.00023	CcSEcCtD
Paricalcitol—Body temperature increased—Betamethasone—psoriasis	6.26e-06	0.00023	CcSEcCtD
Paricalcitol—Insomnia—Prednisone—psoriasis	6.23e-06	0.000229	CcSEcCtD
Paricalcitol—Nausea—Cyclosporine—psoriasis	6.19e-06	0.000228	CcSEcCtD
Paricalcitol—Paraesthesia—Prednisone—psoriasis	6.19e-06	0.000228	CcSEcCtD
Paricalcitol—Pruritus—Triamcinolone—psoriasis	6.17e-06	0.000227	CcSEcCtD
Paricalcitol—Cough—Methotrexate—psoriasis	6.16e-06	0.000227	CcSEcCtD
Paricalcitol—Dizziness—Hydrocortisone—psoriasis	6.13e-06	0.000225	CcSEcCtD
Paricalcitol—Dyspepsia—Prednisone—psoriasis	6.07e-06	0.000223	CcSEcCtD
Paricalcitol—Nausea—Mycophenolate mofetil—psoriasis	6.04e-06	0.000222	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—psoriasis	6.01e-06	0.000221	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—psoriasis	6.01e-06	0.000221	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—psoriasis	6.01e-06	0.000221	CcSEcCtD
Paricalcitol—Decreased appetite—Prednisone—psoriasis	5.99e-06	0.00022	CcSEcCtD
Paricalcitol—Rash—Prednisolone—psoriasis	5.98e-06	0.00022	CcSEcCtD
Paricalcitol—Dermatitis—Prednisolone—psoriasis	5.98e-06	0.00022	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.97e-06	0.000219	CcSEcCtD
Paricalcitol—Fatigue—Prednisone—psoriasis	5.94e-06	0.000219	CcSEcCtD
Paricalcitol—Headache—Prednisolone—psoriasis	5.94e-06	0.000219	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—psoriasis	5.94e-06	0.000218	CcSEcCtD
Paricalcitol—Constipation—Prednisone—psoriasis	5.89e-06	0.000217	CcSEcCtD
Paricalcitol—Vomiting—Hydrocortisone—psoriasis	5.89e-06	0.000217	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.85e-06	0.00285	CbGpPWpGaD
Paricalcitol—Rash—Hydrocortisone—psoriasis	5.84e-06	0.000215	CcSEcCtD
Paricalcitol—Dermatitis—Hydrocortisone—psoriasis	5.84e-06	0.000215	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—PPARG—psoriasis	5.84e-06	0.00284	CbGpPWpGaD
Paricalcitol—Confusional state—Methotrexate—psoriasis	5.81e-06	0.000214	CcSEcCtD
Paricalcitol—Headache—Hydrocortisone—psoriasis	5.8e-06	0.000213	CcSEcCtD
Paricalcitol—Dizziness—Triamcinolone—psoriasis	5.77e-06	0.000212	CcSEcCtD
Paricalcitol—Infection—Methotrexate—psoriasis	5.72e-06	0.00021	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisone—psoriasis	5.68e-06	0.000209	CcSEcCtD
Paricalcitol—Asthenia—Betamethasone—psoriasis	5.68e-06	0.000209	CcSEcCtD
Paricalcitol—Asthenia—Dexamethasone—psoriasis	5.68e-06	0.000209	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—psoriasis	5.65e-06	0.000208	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Prednisone—psoriasis	5.64e-06	0.000207	CcSEcCtD
Paricalcitol—Nausea—Prednisolone—psoriasis	5.63e-06	0.000207	CcSEcCtD
Paricalcitol—Pruritus—Dexamethasone—psoriasis	5.6e-06	0.000206	CcSEcCtD
Paricalcitol—Pruritus—Betamethasone—psoriasis	5.6e-06	0.000206	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—psoriasis	5.6e-06	0.000206	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—psoriasis	5.57e-06	0.000205	CcSEcCtD
Paricalcitol—Vomiting—Triamcinolone—psoriasis	5.55e-06	0.000204	CcSEcCtD
Paricalcitol—Nausea—Hydrocortisone—psoriasis	5.5e-06	0.000202	CcSEcCtD
Paricalcitol—Rash—Triamcinolone—psoriasis	5.5e-06	0.000202	CcSEcCtD
Paricalcitol—Dermatitis—Triamcinolone—psoriasis	5.5e-06	0.000202	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—psoriasis	5.49e-06	0.000202	CcSEcCtD
Paricalcitol—Urticaria—Prednisone—psoriasis	5.48e-06	0.000201	CcSEcCtD
Paricalcitol—Headache—Triamcinolone—psoriasis	5.47e-06	0.000201	CcSEcCtD
Paricalcitol—Abdominal pain—Prednisone—psoriasis	5.45e-06	0.0002	CcSEcCtD
Paricalcitol—Body temperature increased—Prednisone—psoriasis	5.45e-06	0.0002	CcSEcCtD
Paricalcitol—Diarrhoea—Dexamethasone—psoriasis	5.42e-06	0.000199	CcSEcCtD
Paricalcitol—Diarrhoea—Betamethasone—psoriasis	5.42e-06	0.000199	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—psoriasis	5.38e-06	0.000198	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—psoriasis	5.25e-06	0.000193	CcSEcCtD
Paricalcitol—Dizziness—Betamethasone—psoriasis	5.23e-06	0.000192	CcSEcCtD
Paricalcitol—Dizziness—Dexamethasone—psoriasis	5.23e-06	0.000192	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—psoriasis	5.21e-06	0.000192	CcSEcCtD
Paricalcitol—Nausea—Triamcinolone—psoriasis	5.18e-06	0.000191	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—psoriasis	5.17e-06	0.00019	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—psoriasis	5.14e-06	0.000189	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—psoriasis	5.12e-06	0.000188	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisone—psoriasis	5.08e-06	0.000187	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—psoriasis	5.07e-06	0.000186	CcSEcCtD
Paricalcitol—Vomiting—Betamethasone—psoriasis	5.03e-06	0.000185	CcSEcCtD
Paricalcitol—Vomiting—Dexamethasone—psoriasis	5.03e-06	0.000185	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—psoriasis	5.01e-06	0.000184	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CARM1—psoriasis	5.01e-06	0.00244	CbGpPWpGaD
Paricalcitol—Rash—Betamethasone—psoriasis	4.99e-06	0.000184	CcSEcCtD
Paricalcitol—Rash—Dexamethasone—psoriasis	4.99e-06	0.000184	CcSEcCtD
Paricalcitol—Dermatitis—Dexamethasone—psoriasis	4.99e-06	0.000183	CcSEcCtD
Paricalcitol—Dermatitis—Betamethasone—psoriasis	4.99e-06	0.000183	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—psoriasis	4.97e-06	0.000183	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—psoriasis	4.97e-06	0.000183	CcSEcCtD
Paricalcitol—Headache—Betamethasone—psoriasis	4.96e-06	0.000182	CcSEcCtD
Paricalcitol—Headache—Dexamethasone—psoriasis	4.96e-06	0.000182	CcSEcCtD
Paricalcitol—Asthenia—Prednisone—psoriasis	4.95e-06	0.000182	CcSEcCtD
Paricalcitol—Pain—Methotrexate—psoriasis	4.93e-06	0.000181	CcSEcCtD
Paricalcitol—Pruritus—Prednisone—psoriasis	4.88e-06	0.000179	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—psoriasis	4.75e-06	0.000175	CcSEcCtD
Paricalcitol—Diarrhoea—Prednisone—psoriasis	4.72e-06	0.000173	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—psoriasis	4.71e-06	0.000173	CcSEcCtD
Paricalcitol—Nausea—Betamethasone—psoriasis	4.7e-06	0.000173	CcSEcCtD
Paricalcitol—Nausea—Dexamethasone—psoriasis	4.7e-06	0.000173	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—psoriasis	4.58e-06	0.000168	CcSEcCtD
Paricalcitol—Dizziness—Prednisone—psoriasis	4.56e-06	0.000168	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—psoriasis	4.55e-06	0.000167	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—psoriasis	4.55e-06	0.000167	CcSEcCtD
Paricalcitol—Vomiting—Prednisone—psoriasis	4.38e-06	0.000161	CcSEcCtD
Paricalcitol—Rash—Prednisone—psoriasis	4.35e-06	0.00016	CcSEcCtD
Paricalcitol—Dermatitis—Prednisone—psoriasis	4.34e-06	0.00016	CcSEcCtD
Paricalcitol—Headache—Prednisone—psoriasis	4.32e-06	0.000159	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—psoriasis	4.24e-06	0.000156	CcSEcCtD
Paricalcitol—Asthenia—Methotrexate—psoriasis	4.13e-06	0.000152	CcSEcCtD
Paricalcitol—Nausea—Prednisone—psoriasis	4.09e-06	0.000151	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—psoriasis	4.08e-06	0.00015	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—psoriasis	3.94e-06	0.000145	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CAT—psoriasis	3.85e-06	0.00187	CbGpPWpGaD
Paricalcitol—Dizziness—Methotrexate—psoriasis	3.81e-06	0.00014	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—psoriasis	3.66e-06	0.000135	CcSEcCtD
Paricalcitol—Rash—Methotrexate—psoriasis	3.63e-06	0.000134	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—psoriasis	3.63e-06	0.000133	CcSEcCtD
Paricalcitol—Headache—Methotrexate—psoriasis	3.61e-06	0.000133	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—psoriasis	3.42e-06	0.000126	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CAT—psoriasis	3.08e-06	0.0015	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—APOE—psoriasis	2.99e-06	0.00146	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PPARG—psoriasis	2.81e-06	0.00137	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPARG—psoriasis	2.61e-06	0.00127	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—APOE—psoriasis	2.39e-06	0.00116	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPARG—psoriasis	2.08e-06	0.00101	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NDUFA5—psoriasis	1.96e-06	0.000952	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2S1—psoriasis	1.66e-06	0.00081	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CARM1—psoriasis	8.13e-07	0.000395	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CAT—psoriasis	5e-07	0.000243	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—APOE—psoriasis	3.88e-07	0.000189	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPARG—psoriasis	3.38e-07	0.000165	CbGpPWpGaD
